科研之友
微信
新浪微博
Facebook
分享链接
摘要
<正>Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that is characterized by inflammation of the interlobular bile ducts. Although PBC is a slowly progressive disease, with a natural history of 10–15 years leading to end-stage liver disease, highrisk cases may rapidly progress to decompensated cirrhosis or even death. As the most common autoimmune liver disease, the prevalence of PBC has been increasing globally, largely due to increased disease awareness, improved diagnosis, and treatment with ursodeoxycholic acid (UDCA). PBC is more likely to occur in middle-aged women, with a female-to-male ratio ranging from 1.6 to10; however, men have a higher disease severity [1,2].
